Table 3.
Combination drug delivery systems based on liposomes.
| Formulation | Therapeutics | Indication | Status | Targeting | References |
|---|---|---|---|---|---|
| PEG-Liposome | Topotecan + Vincristine | Brain cancer | In vivo | Passive | |
| Polymer-caged nanobins (PCN); Liposome surrounded by cholesterol-terminated poly(acrylic acid) | Cisplatin + Doxorubicin | Various cancers | In vitro | Passive | [67] |
| Liposome | Cytarabine + Daunorubicin | Acute myeloid leukemia | Phase II | Passive | [71] |
| Liposome | Irinotecan + Floxuridine | Colorectal cancer | Phase II | Passive | [72, 73] |
| Mixture of two Liposomes | Irinotecan + Cisplatin | Small-cell lung cancer | In vivo | Passive | [74] |
| PEG-Liposome | Quercetin + Vincristine | Hormone- and TRZ-insensitive breast cancer | In vivo | Passive | [75] |
| Cationic, anionic PEG-Liposome | siRNA + Doxorubicin | MDR-breast cancer | In vivo | Passive | [76] |
| Liposome | 6-Mercaptopurine + Daunorubicin | Acute myeloid leukemia | In vitro | Passive | [77] |
| Transferrin- (Tf-) conjugated PEG-Liposome | Doxorubicin + Verapamil | MDR-leukemia | In vitro | Active (Tf receptor) | [69] |
PEG: polyethylene glycol; MDR: multidrug resistant; TRZ: trastuzumab.